Explore our
Single-cell vs. bulk sequencing: which one to use when?
In 2013, Nature Methods Method of the Year crowned single-cell sequencing as its Method of the Year and the field hasn’t looked back since. What was once impossible is now routine: profiling thousands of individual cells to uncover heterogeneity that bulk approaches simply average out.
Yet progress doesn’t mean replacement. Bulk sequencing still delivers robust, cost-effective insights at scale, while single-cell methods reveal the cellular players driving disease. The real power lies not in choosing one over the other, but in understanding when, and how, to use both.
BioLizard and AbnomX announce partnership
BioLizard and AbnomX announce a strategic partnership to accelerate antibody discovery. Combining BioLizard’s advanced analytics with AbnomX’s Antibody-Extractor platform, the collaboration empowers scientists to transform immune repertoire data into actionable insights.
BioLizard joins BioWin
BioLizard has joined BioWin, Wallonia’s leading health cluster, to collaborate with innovators in biotech, medtech, and research. This partnership strengthens our mission to leverage data for better health outcomes and accelerate life sciences innovation in the region.
BioLizard announces the appointment of André van de Sande as Chairman of the Board
BioLizard appoints André van de Sande as Chairman of the Board. With 30 years of global life sciences experience and a proven track record in pharma, biotech, and consulting, André will guide BioLizard’s international expansion and support its mission in bioinformatics and data-driven life sciences.
BioLizard announces Swiss subsidiary and service offering for AI-powered digital transformation of life sciences at Biopôle in Lausanne
BioLizard launches Swiss subsidiary BioLizard SA at Biopôle in Lausanne, expanding its international presence. The new office offers AI-powered digital transformation services, bioinformatics, and multi-omics solutions to support Swiss biotech clients in drug discovery, diagnostics, and research.
AI in biotech: Fashioning the future of R&D and IP
AI is reshaping biotech R&D, offering powerful insights from complex data while raising key IP protection questions. Experts from BioLizard and Gevers shared how to build AI-ready data, use AI iteratively, and balance patent vs trade secret strategies to secure innovation.
BioLizard and Parean Biotechnologies announce partnership
BioLizard partners with Parean Biotechnologies to advance immune omics insights. Parean’s cutting-edge immune system decoding complements BioLizard’s AI-driven analytics, enabling deeper insights from complex immunological datasets to drive R&D forward.
BioLizard joins Da’s Geniaal consortium
BioLizard has joined the Da’s Geniaal consortium, supporting its mission to inspire 10–14-year-olds—especially girls—to explore science and technology. This partnership aligns with BioLizard’s commitment to sustainability, diversity, equity, and inclusion.
BioLizard launches new AI-empowered “BioVerse” framework to facilitate data-driven R&D for global life sciences community
BioLizard launches the AI-powered Bio|Verse framework, providing tailored software solutions for life sciences R&D. With Bio|Reflect, Pro|Biome, and Bio|Mx, researchers can explore publications, microbiomes, and multi-omics data efficiently, enabling data-driven discovery and biomarker development.
New LLM-based applications developed at the BioLizard Innovation Hackathon
At BioLizard’s first Innovation Hackathon, teams of “Lizards” developed four LLM-based applications in 24 hours, including an AI-generated personalized research newsletter. The event showcased rapid AI-to-practice innovation and strengthened skills for future life sciences applications.